TIGIT and neoplasm: However, administering anti-CD226 mAbs to mice treated with the combination of anti-TIGIT and anti-PD-L1 mAbs or anti-PD-1 and anti-GITR (glucocorticoid-induced TNFR-related protein) mAbs reversed the anti-tumor effect and the survival benefit of the combined treatment, which was accompanied by reduced effector function and frequency of CD8+T cells at the tumor site [42,95].